Victoria Heart Institute Foundation

Victoria, British Columbia VSR 4R2,

2 studies enrolling now · 26 studies all time

What they study most

Acute Coronary Syndrome, Angina Pectoris, Atherosclerotic Cardiovascular Disease, Atrial Fibrillation, Cardiovascular Disease, Congestive Heart Failure, Coronary Artery Bypass Grafting, Coronary Artery Disease, Deep Venous Thrombosis, Heart Failure, Heart Failure With Reduced Ejection Fraction, High Bleeding Risk

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction — Recruiting now
• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) — Completed
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke — Stopped early
• Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry — Completed
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
• LEADERS FREE II: BioFreedom™ Pivotal Study — Running, not enrolling
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass — Completed
• Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina — Completed
• The SOX Trial: Compression Stockings to Prevent the Post-Thrombotic Syndrome — Completed
• ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II — Completed
• Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients — Stopped early
• Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial — Completed
• Study Effect of VIA-2291 on Vascular Inflammation — Completed
• Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial — Completed
• EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan — Completed
• Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) — Stopped early
• A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack — Stopped early